Johnson & Johnson's consumer health business may have turned the corner on its recovery from manufacturing struggles that ended nearly three years ago with a clean bill of health from FDA as orders for OTC drugs increase and e-commerce boosts for personal care product sales.
Analysts say J&J's consumer business results for the first quarter were "encouraging" for its long-term outlook after its worldwide consumer adjusted operational sales – excluding the net impact of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?